Head-to-head evidence
CT-P13 vs etanercept
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
CT-P13 · Inflectra / Remsima
Marketed by Celltrion
NCT01217086 · Phase 3 · completed
The study was randomized, double-blind, and actively controlled with Remicade in 617 participants. However, its primary endpoint was pharmacokinetic equivalence, a surrogate measure, and the registry does not report whether the equivalence comparison was met.
etanercept · Enbrel
Marketed by Amgen
NCT03780959 · Phase 2/3 · completed
After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-P13's landscape · etanercept's landscape